Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer

•Recurrent resistant uterine cancer patients have a poor prognosis with limited treatment options.•Pembrolizumab is a PD1-inhibitor that was recently FDA approved for MMR-deficient solid tumors, including uterine cancer.•Pembrolizumab can produce long-term durable response in resistant, refractory endometrial cancer with minimal side effects.